AnaptysBio, Inc. Logo

AnaptysBio, Inc.

ANAB

(0.8)
Stock Price

14,55 USD

-39.8% ROA

-287.94% ROE

-5.2x PER

Market Cap.

976.963.530,00 USD

3682.87% DER

0% Yield

-289.75% NPM

AnaptysBio, Inc. Stock Analysis

AnaptysBio, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AnaptysBio, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (15%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-84.21%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-31.19%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (3.29x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-2) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

AnaptysBio, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AnaptysBio, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

AnaptysBio, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AnaptysBio, Inc. Revenue
Year Revenue Growth
2013 5.483.000
2014 15.838.000 65.38%
2015 17.571.000 9.86%
2016 16.684.000 -5.32%
2017 10.000.000 -66.84%
2018 5.000.000 -100%
2019 8.000.000 37.5%
2020 75.000.000 89.33%
2021 63.175.000 -18.72%
2022 10.287.000 -514.12%
2023 13.272.000 22.49%
2023 17.157.000 22.64%
2024 43.884.000 60.9%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AnaptysBio, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 8.820.000
2014 8.614.000 -2.39%
2015 17.304.000 50.22%
2016 15.419.000 -12.23%
2017 29.443.000 47.63%
2018 56.196.000 47.61%
2019 99.338.000 43.43%
2020 80.025.000 -24.13%
2021 98.496.000 18.75%
2022 88.798.000 -10.92%
2023 123.512.000 28.11%
2023 132.283.000 6.63%
2024 167.372.000 20.96%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AnaptysBio, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 1.950.000
2014 2.354.000 17.16%
2015 3.589.000 34.41%
2016 4.290.000 16.34%
2017 9.338.000 54.06%
2018 15.526.000 39.86%
2019 16.094.000 3.53%
2020 18.854.000 14.64%
2021 21.493.000 12.28%
2022 36.643.000 41.34%
2023 40.688.000 9.94%
2023 41.946.000 3%
2024 37.180.000 -12.82%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AnaptysBio, Inc. EBITDA
Year EBITDA Growth
2013 -4.706.000
2014 5.180.000 190.85%
2015 -3.255.000 259.14%
2016 -3.045.000 -6.9%
2017 -26.929.000 88.69%
2018 -60.196.000 55.26%
2019 -96.447.000 37.59%
2020 -19.372.000 -397.87%
2021 -56.346.000 65.62%
2022 -107.592.000 47.63%
2023 -129.140.000 16.69%
2023 -135.825.000 4.92%
2024 -158.904.000 14.52%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AnaptysBio, Inc. Gross Profit
Year Gross Profit Growth
2013 -3.337.000
2014 7.224.000 146.19%
2015 267.000 -2605.62%
2016 1.265.000 78.89%
2017 -19.443.000 106.51%
2018 -51.196.000 62.02%
2019 -91.338.000 43.95%
2020 -5.025.000 -1717.67%
2021 -35.321.000 85.77%
2022 7.952.000 544.18%
2023 13.272.000 40.08%
2023 14.781.000 10.21%
2024 41.504.000 64.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AnaptysBio, Inc. Net Profit
Year Net Profit Growth
2013 -5.545.000
2014 3.532.000 256.99%
2015 -5.405.000 165.35%
2016 -4.259.000 -26.91%
2017 -30.070.000 85.84%
2018 -61.656.000 51.23%
2019 -97.336.000 36.66%
2020 -19.920.000 -388.63%
2021 -57.193.000 65.17%
2022 -128.724.000 55.57%
2023 -149.232.000 13.74%
2023 -163.619.000 8.79%
2024 -186.640.000 12.33%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AnaptysBio, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 -2 100%
2018 -3 50%
2019 -4 33.33%
2020 -1 0%
2021 -2 100%
2022 -5 50%
2023 -6 20%
2023 -6 16.67%
2024 -7 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AnaptysBio, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -5.833.000
2014 14.458.000 140.34%
2015 -9.907.000 245.94%
2016 -9.080.000 -9.11%
2017 -19.728.000 53.97%
2018 -49.569.000 60.2%
2019 -70.322.000 29.51%
2020 -14.726.000 -377.54%
2021 -47.286.000 68.86%
2022 -73.951.000 36.06%
2023 -36.636.000 -101.85%
2023 -121.607.000 69.87%
2024 -14.415.000 -743.61%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AnaptysBio, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -5.796.000
2014 14.603.000 139.69%
2015 -9.669.000 251.03%
2016 -9.030.000 -7.08%
2017 -19.438.000 53.54%
2018 -48.506.000 59.93%
2019 -69.517.000 30.22%
2020 -14.157.000 -391.04%
2021 -45.920.000 69.17%
2022 -73.593.000 37.6%
2023 -36.474.000 -101.77%
2023 -120.800.000 69.81%
2024 -14.382.000 -739.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AnaptysBio, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 37.000
2014 145.000 74.48%
2015 238.000 39.08%
2016 50.000 -376%
2017 290.000 82.76%
2018 1.063.000 72.72%
2019 805.000 -32.05%
2020 569.000 -41.48%
2021 1.366.000 58.35%
2022 358.000 -281.56%
2023 162.000 -120.99%
2023 807.000 79.93%
2024 33.000 -2345.45%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AnaptysBio, Inc. Equity
Year Equity Growth
2013 145.000
2014 5.993.000 97.58%
2015 42.337.000 85.84%
2016 39.268.000 -7.82%
2017 307.581.000 87.23%
2018 486.365.000 36.76%
2019 405.008.000 -20.09%
2020 396.731.000 -2.09%
2021 356.428.000 -11.31%
2022 262.103.000 -35.99%
2023 88.103.000 -197.5%
2023 120.383.000 26.81%
2024 9.879.000 -1118.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AnaptysBio, Inc. Assets
Year Assets Growth
2013 3.914.000
2014 25.065.000 84.38%
2015 56.280.000 55.46%
2016 62.180.000 9.49%
2017 329.364.000 81.12%
2018 508.997.000 35.29%
2019 435.197.000 -16.96%
2020 416.552.000 -4.48%
2021 643.070.000 35.22%
2022 610.383.000 -5.36%
2023 452.389.000 -34.92%
2023 487.326.000 7.17%
2024 427.376.000 -14.03%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AnaptysBio, Inc. Liabilities
Year Liabilities Growth
2013 3.769.000
2014 19.072.000 80.24%
2015 13.943.000 -36.79%
2016 22.912.000 39.15%
2017 21.783.000 -5.18%
2018 22.632.000 3.75%
2019 30.189.000 25.03%
2020 19.821.000 -52.31%
2021 286.642.000 93.09%
2022 348.280.000 17.7%
2023 364.286.000 4.39%
2023 366.943.000 0.72%
2024 417.497.000 12.11%

AnaptysBio, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.11
Net Income per Share
-6.22
Price to Earning Ratio
-5.2x
Price To Sales Ratio
32.06x
POCF Ratio
-6.84
PFCF Ratio
-7.52
Price to Book Ratio
89.58
EV to Sales
42.14
EV Over EBITDA
-8.55
EV to Operating CashFlow
-9.92
EV to FreeCashFlow
-9.89
Earnings Yield
-0.19
FreeCashFlow Yield
-0.13
Market Cap
0,98 Bil.
Enterprise Value
1,28 Bil.
Graham Number
7.11
Graham NetNet
-2.19

Income Statement Metrics

Net Income per Share
-6.22
Income Quality
0.76
ROE
-2.56
Return On Assets
-0.34
Return On Capital Employed
-0.33
Net Income per EBT
1
EBT Per Ebit
1.12
Ebit per Revenue
-2.58
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
1.38
Research & Developement to Revenue
4.7
Stock Based Compensation to Revenue
1.1
Gross Profit Margin
0.96
Operating Profit Margin
-2.58
Pretax Profit Margin
-2.9
Net Profit Margin
-2.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-4.73
Free CashFlow per Share
-4.75
Capex to Operating CashFlow
-0
Capex to Revenue
0.02
Capex to Depreciation
0.21
Return on Invested Capital
-0.46
Return on Tangible Assets
-0.4
Days Sales Outstanding
107.88
Days Payables Outstanding
744.93
Days of Inventory on Hand
0
Receivables Turnover
3.38
Payables Turnover
0.49
Inventory Turnover
2396000
Capex per Share
0.02

Balance Sheet

Cash per Share
12,82
Book Value per Share
0,36
Tangible Book Value per Share
0.36
Shareholders Equity per Share
0.36
Interest Debt per Share
14.27
Debt to Equity
36.83
Debt to Assets
0.85
Net Debt to EBITDA
-2.04
Current Ratio
9.09
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,05 Bil.
Invested Capital
344054000
Working Capital
0,33 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
1
Debt to Market Cap
0.37

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AnaptysBio, Inc. Dividends
Year Dividends Growth

AnaptysBio, Inc. Profile

About AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CEO
Mr. Daniel R. Faga
Employee
117
Address
10770 Wateridge Circle
San Diego, 92121-5801

AnaptysBio, Inc. Executives & BODs

AnaptysBio, Inc. Executives & BODs
# Name Age
1 Ms. Beth Mueller
Senior Vice President of Human Resources
70
2 Mr. Benjamin Stone
Chief Business Officer
70
3 Mr. Douglas A. Rich M.B.A.
Senior Vice President of CMC
70
4 Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
70
5 Dr. Martin Dahl Ph.D.
Senior Vice President of Research
70
6 Mr. Daniel R. Faga
President, Chief Executive Officer & Director
70
7 Mr. Dennis M. Mulroy
Chief Financial Officer
70
8 Mr. Eric J. Loumeau
Chief Legal Officer
70
9 Ms. Monique Da Silva
Senior Vice President of Corporate Affairs
70
10 Ms. Priya Raina
Senior Vice President of Clinical Operations
70

AnaptysBio, Inc. Competitors